152 related articles for article (PubMed ID: 37861026)
1. The Use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
Martín-García D; Téllez T; Redondo M; García-Aranda M
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37861026
[TBL] [Abstract][Full Text] [Related]
2. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
Muñoz M; Coveñas R
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202
[TBL] [Abstract][Full Text] [Related]
3. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Robinson P; Coveñas R; Muñoz M
Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
[TBL] [Abstract][Full Text] [Related]
5. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
6. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
7. Advances in the research and application of neurokinin-1 receptor antagonists.
Hong X; Ma J; Zheng S; Zhao G; Fu C
J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
[TBL] [Abstract][Full Text] [Related]
8. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
9. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
10. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.
Isorna I; González-Moles MÁ; Muñoz M; Esteban F
J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053
[TBL] [Abstract][Full Text] [Related]
11. Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity.
Legi A; Rodriguez E; Eckols TK; Mistry C; Robinson P
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917491
[No Abstract] [Full Text] [Related]
12. Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients.
Robinson P; Rosso M; Muñoz M
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983138
[TBL] [Abstract][Full Text] [Related]
13. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
14. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
Golestaneh M; Firoozrai M; Javid H; Hashemy SI
Mol Biol Rep; 2022 Jun; 49(6):4893-4900. PubMed ID: 35429316
[TBL] [Abstract][Full Text] [Related]
15. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
Muñoz M; Rosso M
Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
[TBL] [Abstract][Full Text] [Related]
16. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
18. Biological and Pharmacological Aspects of the NK1-Receptor.
Garcia-Recio S; Gascón P
Biomed Res Int; 2015; 2015():495704. PubMed ID: 26421291
[TBL] [Abstract][Full Text] [Related]
19. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
[TBL] [Abstract][Full Text] [Related]
20. [Neurokinin 1 receptor antagonists--between hope and disappointment].
Rost K; Fleischer F; Nieber K
Med Monatsschr Pharm; 2006 Jun; 29(6):200-5. PubMed ID: 16792196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
